EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Therapeutic Modulation of IL ‐6/ STAT ‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study

Khlood Mohammad Aldossary iD, Mahmoud S Abdallah iD, Noha Kamal iD, Mounir M Bahgat iD, Sarah Alrubia, Amsha S Alsegiani, Mostafa M Bahaa iD, Ahmed S Hassan, Eman El-Khateeb iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70088 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Khlood Mohammad Aldossary und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Fenofibrate, Interleukin-6, Nitric Oxide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peroxisome proliferator‐activated receptor α (PPARα) has been reported to exert protective roles in immune‐mediated intestinal diseases through inhibition of interleukin‐6 (IL‐6)‐induced signal transducer and activator of transcription factor 3 (STAT3) activation.

Aim

To investigate the potential anti‐inflammatory effect of fenofibrate, as an add‐on therapy to mesalamine, on IL‐6/STAT3 and nitric oxide (NO) in patients with ulcerative colitis (UC).

Methods

This pilot, double‐blind, randomized, controlled trial included 60 patients diagnosed with mild‐to‐moderate UC. Patients were randomly allocated into two groups. The placebo group ( n = 30) received placebo plus mesalamine 1 g three times daily, and the fenofibrate group ( n = 30) received mesalamine 1 g three times daily and fenofibrate 160 mg once daily. The study duration was 6 months. The severity of UC was evaluated using the Disease Activity Index (DAI), and quality of life (QoL) was assessed using the Short Form‐36 questionnaire (SF‐36). Serum levels of IL‐6, NO, C‐reactive protein (CRP), and STAT3 were measured for all patients.

Results

After treatment, both groups showed a significant reduction in DAI, IL‐6, STAT3, NO, and CRP, along with an increase in SF‐36 scores. Furthermore, the fenofibrate group demonstrated a significantly greater decrease in DAI ( p = 0.0002), IL‐6 ( p = 0.04), STAT3 ( p = 0.004), NO ( p = 0.013), and CRP ( p = 0.034), as well as a greater increase in SF‐36 ( p = 0.04) compared with the placebo group.

Conclusion

Fenofibrate may represent a promising add‐on therapy in patients with mild‐to‐moderate UC by modulating inflammation and improving QoL. Trial Registration NCT05753267

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeFenofibrateInterleukin-6Nitric OxideSTAT3 Transcription FactorAdultFemaleHumansMaleMiddle AgedC-Reactive ProteinDouble-Blind MethodDrug Therapy, CombinationMesalaminePilot ProjectsQuality of LifeSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

IL‐6/STAT3NOPPARαSF‐36fenofibrateulcerative colitis

Substanzen

C-Reactive ProteinFenofibrateIL6 protein, humanInterleukin-6MesalamineNitric OxideSTAT3 protein, humanSTAT3 Transcription Factor

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, Menoufia, Egypt.
  • Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
  • Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University-Egypt (HUE), New Damietta, Egypt.

ORCID-Profile: Khlood Mohammad Aldossary, Mahmoud S Abdallah, Noha Kamal, Mounir M Bahgat, Mostafa M Bahaa, Eman El-Khateeb

Zitieren

APA

Aldossary, K. M., Abdallah, M. S., Kamal, N., Bahgat, M. M., Alrubia, S., Alsegiani, A. S., Bahaa, M. M., Hassan, A. S., & El-Khateeb, E. (2025). Therapeutic Modulation of IL ‐6/ STAT ‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70088

Vancouver

Aldossary KM, Abdallah MS, Kamal N, Bahgat MM, Alrubia S, Alsegiani AS, et al. Therapeutic Modulation of IL ‐6/ STAT ‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70088

BibTeX
@article{Aldossary2025,
  author = {Aldossary, Khlood Mohammad and Abdallah, Mahmoud S and Kamal, Noha and Bahgat, Mounir M and Alrubia, Sarah and Alsegiani, Amsha S and Bahaa, Mostafa M and Hassan, Ahmed S and El-Khateeb, Eman},
  title = {Therapeutic Modulation of IL ‐6/ STAT ‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70088}
}
Kostenlos starten →